Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

Desai, Aakash; Abdayem, Pamela; Adjei, Alex A.; Planchard, David

doi:10.1016/j.lungcan.2021.12.002

Cited by 48 publications

(19 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these patients the risk of disease progression or death was lower among who received trastuzumab deruxtecan than among who received trastuzumab emtansine ( 37 ). In this way, future development of rovalpituzumab, as mAb targeting DLL3 in the structure of an ADC, could include a different and more consistent linker, an increasing payload loading, novel and more powerful payloads or more innovative payloads that could overcome resistance to previous therapies ( 38 ).…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

et al. 2022

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces the efficacy of applying the treatment to the entire population of patients with SCLC. The lack of treatments able to bind to a specific target has always been a substantial difference to the non-small cell lung cancer (NSCLC) counterpart. Delta-like canonical Notch ligand 3 is a protein frequently overexpressed in SCLC and is therefore being explored as a potentially promising therapeutic target in high-grade neuroendocrine lung cancer. In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failures through new compounds and their possible applications in clinical practice, with a focus on new molecular classification of SCLC.

show abstract

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Much progress has been made with ADCs in HER2‐mutant NSCLC. The investigations into other targets, including HER3, TROP2, CEACAM5 and MET in NSCLC are still ongoing [ 306 ]. TTFields, a low intensity, intermediate frequency, alternating electric fields, is one of physical therapy in cancer.…”

Section: Treatmentmentioning

confidence: 99%

Non‐small cell lung cancer in China

Chen

Liu

Wen

et al. 2022

Cancer Communications

225

View full text Add to dashboard Cite

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.

show abstract

“…In recent years, with the rapid development of ADCs, they have also shown good efficacy in the field of NSCLC. The main targets involved include human epidermal growth factor 2 (Her2), human epidermal growth factor 2 (Her3), and tumor-associated calcium signal transducer 2 (Trop-2), which are all in the clinical trial stage ( Desai et al, 2022 ).…”

Section: Antibody Therapy In Nsclcmentioning

confidence: 99%

Current status of immunotherapy for non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them, non-small cell lung cancer (NSCLC) accounts for 80%∼85% of all lung cancers, and its 5-year survival rate is less than 15%, making the situation critical. In the past decades, despite some clinical advances in conventional treatments, the overall survival rate of NSCLC is still not optimistic due to its unique physiological conditions and the frequent occurrence of tumor escape. In recent years, immunotherapy has become a new hot spot in lung cancer research, including antibody therapy and cell therapy, which have been developed and utilized one after another, especially immune checkpoint inhibitor (ICI). These approaches have effectively improved the overall survival rate and objective response rate of NSCLC patients by enhancing the immune capacity of the body and targeting tumor cells more effectively, which is more specific and less toxic compared with conventional chemotherapy, and providing more strategies for NSCLC treatment. In this paper, we reviewed the relevant targets, clinical progress and adverse reaction in monoclonal antibodies, antibody-drug conjugates, ICI, bispecific antibodies, T-cell receptor engineered T cell therapy (TCR-T), Chimeric antigen receptor T-cell immunotherapy (CAR-T), and also report on their combination therapy from the immune-related background to provide better NSCLC treatment and prospective.

show abstract

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

Cited by 48 publications

References 60 publications

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

Non‐small cell lung cancer in China

Current status of immunotherapy for non-small cell lung cancer

Contact Info

Product

Resources

About